Loading...

TERN TERNS PHARMACEUTICALS INC Expansion Plans 8-K Filing

TRNS

TRN

TERNS PHARMACEUTICALS INC

(TERN)

2025 8-K

Merger Completed

FDA Approval News

Merger Announcement

License Agreement Update

Company Priorities Update

Public Offering Announcement

Clinical Trial Update

Financial Results Report

Clinical Trial Results

Financial Statements

Financial Statements

Financial Results

Management Change

Management Changes

Financial Update

Financial Results

Public Offering

Positive Trial Results

Earnings Reports

Executive Leadership Transi...

Lease Extension

Earnings Reports

Financial Results Announcement

Appointment of CEO and Dire...

Earnings Reports

Bylaws Amendment

Earnings Reports

Leadership Transition

Sales Agreement

Earnings Reports

Financial Results Announcement

Assurance of Operations and...

External Links:

On October 21, 2025, Terns Pharmaceuticals, Inc. announced topline results from a 12-week Phase 2 trial of TERN-601, an oral treatment for obesity. This filing is significant as it reports on the company's potential new drug development.

AI Assistant

TERNS PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.